Original Article Clinical Experience on Usage of Apixaban in Thrombosis Management Study (CEATMS): Clinical Experience on Usage of Apixaban in Thrombosis Management Study (CEATMS)

Manjula S

doi:10.15713/ins.bhj.151

Authors

Manjula S VP- Department of Medical Services, Micro Labs Ltd

DOI:

https://doi.org/10.15713/ins.bhj.151

Keywords:

Oral anticoagulation therapy, Prophylaxis, Thromboembolic conditions

Abstract

Oral anticoagulation therapy (OAT) has been increasing in clinical practice for the prophylaxis and treatment of thromboembolic conditions, such as atrial fibrillation (AF). Warfarin is the standard of care, but its disadvantages include interactions with drugs and food, slow onset of action, and narrow therapeutic index. Non-VKA oral anticoagulants (NOACs) such as dabigatran, rivaroxaban, and apixaban are now approved for prevention of thrombosis in both NVAF and VTE. The aim of the present study is to explicate the use of NOACs in various thromboembolic disorders.

References

Blann AD, Landray MJ, Lip GYH. ABC of antithrombotic therapy: An overview of antithrombotic therapy. BMJ. 2002 Oct 5;325(7367):762–5.

David Livingston J, John Mj. Knowledge base and practice among clinicians regarding oral anticoagulant therapy: A questionnaire survey. CHRISMED Journal of Health and Research. 2017;4(3):166.

Benjamin EJ, Wolf PA, D RB, Silbershatz H, Kannel WB, Levy D. Impact of Atrial Fibrillation on the Risk of Death The Framingham Heart Study. 1998 [cited 2023 May 30]; Available from: http://ahajournals.org

Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991 Aug;22(8):983–8.

Kirley K, Qato DM, Kornfield R, Stafford RS, Caleb Alexander G. NATIONAL TRENDS IN ORAL ANTICOAGULANT USE IN THE UNITED STATES, 2007-2011.

Hellwig T, Gulseth M. New oral therapies for the prevention and treatment of venous thromboembolism. Am J Health Syst Pharm. 2013 Jan 15;70(2):113–25.

Deep Chandh Raja AK. Epidemiology of Atrial Fibrillation - An Indian Perspective. Journal of the association of physicians of India.

Borde T, Prasad C, Arimappamagan A, Srinivas D, Somanna S. Incidence of deep venous thrombosis in patients undergoing elective neurosurgery – A prospective cohort based study. Neurol India. 2017;65(4):787.

Saggu DK, Rangaswamy VV, Yalagudri S, Sundar G, Reddy NK, Shah V, et al. Prevalence, clinical profile, and stroke risk of atrial fibrillation in rural Andhra Pradesh, India (the AP-AF study). Indian Heart J. 2022 Mar;74(2):86–90.

Maisel WH, Stevenson LW. Atrial fibrillation in heart failure: epidemiology, pathophysiology, and rationale for therapy. Am J Cardiol. 2003 Mar 20;91(6A):2D-8D.

Kannel WB, Wolf PA, Benjamin EJ, Levy D. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol. 1998 Oct 16;82(8A):2N-9N.

Vene N, Mavri A. An Overview of the Anticoagulant Drugs Used in Routine Clinical Practice. In: Anticoagulant Drugs. InTech; 2018.

Chen A, Stecker E, Warden BA. Direct oral anticoagulant use: A practical guide to common clinical challenges. J Am Heart Assoc. 2020 Jul 7;9(13).